NÍOSYNC LIMITED

NíoSync is a pan‑European commercialisation platform dedicated to specialty biopharmaceutical products. By acquiring clinically proven therapies, the company creates a clear, capital‑efficient route for biopharma innovators to bring their medicines into Europe’s complex and fragmented markets, ensuring that new treatments reach patients fairly, efficiently and at scale.

The firm’s core services combine deep regulatory expertise, market intelligence and strategic partnerships. This infrastructure accelerates patient access, optimises value for payers and providers, and rewards innovation that improves outcomes. NíoSync also offers non‑dilutive capital to biopharma partners, acquiring rights to commercial or pre‑commercial therapeutic assets and supporting their strategic objectives without diluting existing shareholders.

Targeting biopharma innovators seeking a viable path to monetise clinically proven medicines, NíoSync delivers new treatment options to patients while providing a sustainable commercial model for its partners across Europe.